Single-dose universal hepatitis a immunization in one-year-old children in Argentina: High prevalence of protective antibodies up to 9 years after vaccination

Pediatric Infectious Disease Journal

Volumn 35, Issue 12, 2016, Pages 1339-1342

  Urueña, Analía ^a   González, Jorge E ^b   Rearte, Analía ^a   Pérez Carrega, María E ^a   Calli, Rogelio ^a   Pagani, María F ^c   Uboldi, Andrea ^a   Vicentín, Rosalía ^d   Caglio, Patricia ^e   Cañero Velasco, María C ^f   Gentile, Angela ^g   Ramonet, Margarita ^h   Vizzotti, Carla ^a  

^a National Ministry of Health   (Argentina)

^b INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^c Hospital del Nino Jesus Argentina   (Argentina)

^d 'O Alassia' Children's Hospital   (Argentina)

^e HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^f Hospital de Ninos de San Justo   (Argentina)

^g HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^h Ministerio Salud de la Provincia de Buenos Aires   (Argentina)

Author keywords

Argentina; Children; Hepatitis A; Immunogenicity; Long term follow up; Single dose vaccination

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ARGENTINA; ARTICLE; BLOOD SAMPLING; CHILD; DEMOGRAPHY; FEMALE; HEPATITIS A; HUMAN; INFECTION PREVENTION; MALE; PREVALENCE; PRIORITY JOURNAL; SEROPREVALENCE; SINGLE DRUG DOSE; SOCIOECONOMICS; VACCINATION; BLOOD; FOLLOW UP; HEPATITIS A VIRUS; IMMUNOLOGY; INFANT;

ARGENTINA; CHILD; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HUMANS; INFANT; MALE; PREVALENCE;

EID: 84987864015     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001322     Document Type: Article

References (32)

1. Findor JA, Caiero Velasco MC, Mutti J, et al. Response to hepatitis A vaccine in children after a single dose with a booster administration 6 months later. J Travel Med. 1996;3:156-159.
2. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 1992;327:453-457.
3. Lopez EL, Contrini MM, Xifri MC, et al. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. Vaccine. 2007;25:102-108.
4. Mayorga Perez O, Herzog C, Zellmeyer M, et al. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebocontrolled trial. J Infect Dis. 2003;188:671-677.
5. Averhoff F, Shapiro CN, Bell BP, et al. Control of hepatitis A through routine vaccination of children. JAMA. 2001;286:2968-2973.
6. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. 2005;294:194-201.
7. Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA. 2005;294:202-210.
8. Fangcheng Z, Xuanyi W, Mingding C, et al. Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China. Hepat Mon. 2012;12:100-105.
9. Ministerio de Salud y Ambiente, Argentina. Resoluci?n 653/05, 113(30677). Buenos Aires, Argentina: Bolet?n Oficial de la Rep?blica Argentina; 2005: 3.
10. Gentile A, Ramonet M, Ellis A. An?lisis sobre la necesidad de la incorporaci?n de la vacuna contra hepatitis A en la Argentina. Comit? Nacional de Infectolog?a, Sociedad Argentina de Pediatria. Arch Argent Pediatr. 2004;102:487-498.
11. Ciocca M, Moreira-Silva SF, Alegria S, et al. Hepatitis A as an etiologic agent of acute liver failure in Latin America. Pediatr Infect Dis J. 2007;26:711-715.
12. Ciocca M, Ramonet M, Cuarterolo M, et al. Acute liver failure in children: experience with 210 patients. J Pediatr Gastroenterol Nutr. 2004;39:S31.
13. Ciocca M, Ramonet M, Cuarterolo M, et al. Prognostic factors in paediatric acute liver failure. Arch Dis Child. 2008;93:48-51.
14. Hatz C, van der Ploeg R, Beck BR, et al. Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years. Clin Vaccine Immunol. 2011;18:885-887.
15. Melgac JG, Morgado LN, Santiago MA, et al. A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection. Vaccine. 2015;33:3813-3820.
16. Barkai G, Belmaker I, Givon-Lavi N, et al. The effect of universal toddlersonly hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community. Pediatr Infect Dis J. 2009;28:391-393.
17. Chan CY, Lee SD, Yu MI, et al. Long-term follow-up of hepatitis A vaccination in children. Vaccine. 1999;17:369-372.
18. Fan PC, Chang MH, Lee PI, et al. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine. 1998;16:232-235.
19. Gentile A. The need for an evidence-based decision-making process with regard to control of hepatitis A. J Viral Hepat. 2008;15(suppl 2):16-21.
20. Cervio G, Trentadue J, D'Agostino D, et al. Decline in HAV-Associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program. Hepat Med. 2011;3:99-106.
21. Vizzotti C, Gonzalez J, Gentile A, et al. Impact of the single-dose immunization strategy against hepatitis A in Argentina. Pediatr Infect Dis J. 2014;33:84-88.
22. Vizzotti C, Gonzalez J, Rearte A, et al. Single-dose universal hepatitis A immunization in Argentina: low viral circulation and high persistence of protective antibodies up to 4 years. J Pediatric Infect Dis Soc. 2015;4: e62-e67.
23. World Health Organization. WHO position paper on hepatitis A vaccines. Weekly epidemiological record. 2012;87:261-276.
24. Gonzalez J, Fay O, Canero-Velasco MC, et al. [Hepatitis A virus infection in children in Argentina: a pilot study]. Acta Gastroenterol Latinoam. 1997;27:331-334.
25. World Health Organization. The Immunological Basis for Immunization Series Module 18: Hepatitis A. Immunization, Vaccines and Biologicals. 2011. Available at http://apps.who.int/iris/bitstream/10665/44570/1/9789241501422-eng.pdf.
26. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-7):1-23.
27. Espul C, Benedetti L, Linares M, et al. Five-year follow-up of immune response after one or two doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. J Viral Hepat. 2015;22:453-458.
28. Mayorga Perez O, Brinkhof MW, Egger M, et al. Decreasing risk of hepatitis A infection in Le?n, Nicaragua: evidence from cross-sectional and longitudinal seroepidemiology studies. PLoS One. 2014;9:e87643.
29. Blanco Fernandez MD, Torres C, Riviello-Lopez G, et al. Analysis of the circulation of hepatitis A virus in Argentina since vaccine introduction. Clin Microbiol Infect. 2012;18:E548-E551
30. Yanez LA, Lucero NS, Barril PA, et al. Evidence of hepatitis A virus circulation in central Argentina: seroprevalence and environmental surveillance. J Clin Virol. 2014;59:38-43.
31. Xu ZY, Li ZH, Wang JX, et al. Ecology and prevention of a shellfish-Associated hepatitis A epidemic in Shanghai, China. Vaccine. 1992;10(suppl 1):S67-S68.
32. Levine H, Kopel E, Anis E, et al. The impact of a national routine immunisation programme initiated in 1999 on Hepatitis A incidence in Israel, 1993 to 2012. Euro Surveill. 2015;20:3-10.